Read More

Amgen/AstraZeneca’s Asthma Drug Tezspire Vs. Sanofi/Regeneron’s Blockbuster Dupixent – Analyst Gives His Pick

Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300 cells/μL.

AMGN

Read More

Stocks Fall As Geopolitics, Economic Worries Spook Investors, Chipmakers Sell Off, Bitcoin Tumbles To $60,000: What’s Driving Markets Wednesday?

A sentiment of risk aversion looms over the markets during Wednesday’s trading session, triggering midday losses across the board in stocks and cryptocurrencies and prompting a flight towards bonds, as investor confidence remains dampened by geopolitical and economic risks.

AA

Read More

Election Impact: Analyst Eyes Potential Upside for Strategic Education with Republican Victory

Truist Securities analyst boosts STRA's rating to Buy, citing robust enrollment prospects in U.S. adult education and potential margin gains from a high fixed-cost model. With a price target increase to $125, Sommer anticipates upward estimate revisions and potential multiple expansion, especially if Republicans reclaim the White House.

STRA